Interferon-induced autoimmune thyroiditis in a patient with hepatitis C virus infection;Tiroiditis autoinmune inducida por interferón en paciente con infección por virus de la hepatitis C.

Revista Peruana de Medicina Experimental y Salud Publica

Volumn 28, Issue 2, 2011, Pages 382-384

  Pinto, José L ^a,b   Pinto, Miguel E ^a,b  

^a HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

Graves Disease; Hepatitis C; Hyperthyroidism; Interferons; Thyroiditis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; RIBAVIRIN; THYROID ANTIBODY; THYROID HORMONE; THYROTROPIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; AUTOIMMUNE THYROIDITIS; CASE REPORT; FOLLOW UP; GRAVES DISEASE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; LIVER BIOPSY; MALE;

EID: 80052165580     PISSN: 17264634     EISSN: 17264642     Source Type: Journal    
DOI: 10.1590/S1726-46342011000200028     Document Type: Article

References (18)

1. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007;36:1051-66.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
3. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
4. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711-19.
5. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Interferon-α-related thyroid disease: Pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89:3656-61.
6. Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab. 2009;23:703-12.
7. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
8. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436-41.
9. Killenberg PG. Extrahepatic manifestations of chronic hepatitis C. Semin Gastrointest Dis. 2000;11:62-8.
10. Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006;8:53-9.
11. Andrade LJ, Atta AM, D'Almeida Junior A, Paraná R. Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin-a review. Braz J Infect Dis. 2008;12:144-8.
12. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43:661-72.
13. Doi F, Kakizaki S, Takagi H, Murakami M, Sohara N, Otsuka T, et al. Long-term outcome of interferon-alphainduced autoimmune thyroid disorders in chronic hepatitis C. Liver Int. 2005;25:242-6.
14. Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, Lu SN, et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol. 2006;21:319-26.
15. Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. J Viral Hepat. 2009;16:168-77.
16. Prummel MF, Laurberg P. Interferon-α and autoimmune thyroid disease. Thyroid. 2003;13:547-51.
17. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun. 2010;34:J322-6.
18. Kong YM, Wei WZ, Tomer Y. Opportunistic autoimmune disorders. Ann N Y Acad Sci. 2010;1183:222-36.